Prothena | PRTA - Gross Profit On Sales

Stock Price
8.52
Daily Change
-0.07 -0.81%
Monthly
-5.54%
Yearly
-33.80%
Q1 Forecast
8.93

Prothena reported $2.42M in Gross Profit on Sales for its fiscal quarter ending in September of 2025.





Gross Profit On Sales Change Date
Acadia Pharmaceuticals USD 257.76M 778K Dec/2025
Agios Pharmaceuticals USD 18.09M 6.89M Dec/2025
Akebia Therapeutics USD 47.28M 1.7M Dec/2025
ALKERMES USD 338.34M 72.51M Dec/2025
Alnylam Pharmaceuticals USD 829.31M 219.56M Dec/2025
Amgen USD 6.48B 307M Sep/2025
Biogen USD 1.65B 34.6M Dec/2025
BioMarin Pharmaceutical USD 713.01M 81.81M Dec/2025
Exelixis USD 572.18M 7M Dec/2025
Immunic 0 0 Mar/2025
Incyte USD 1.39B 118.68M Dec/2025
Ionis Pharmaceuticals USD 195M 40M Dec/2025
MacroGenics USD 31.11M 30.14M Dec/2025
Nektar Therapeutics USD 13.75M 650K Jun/2024
Neurocrine Biosciences USD 787.9M 7M Dec/2025
Prothena USD 2.42M 38.52M Sep/2025
Regeneron Pharmaceuticals USD 3.3B 67M Dec/2025
Ultragenyx Pharmaceutical USD 178M 46.06M Dec/2025
Vertex Pharmaceuticals USD 2.72B 62.4M Dec/2025
Xoma 992K 846K Jun/2024